Menu
Search
|

Menu

Close
X

Regeneron Pharmaceuticals Inc REGN.OQ (NASDAQ Stock Exchange Global Select Market)

332.15 USD
-1.03 (-0.31%)
As of Feb 16
chart
Previous Close 333.18
Open 334.00
Volume 387,449
3m Avg Volume 325,481
Today’s High 341.00
Today’s Low 329.00
52 Week High 543.50
52 Week Low 313.86
Shares Outstanding (mil) 107.44
Market Capitalization (mil) 35,686.07
Forward P/E 32.18
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.33 Mean rating from 27 analysts

KEY STATS

Revenue (mm, USD)
FY17
5,872
FY16
4,860
FY15
4,104
EPS (USD)
FY17
10.321
FY16
7.737
FY15
5.509
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
32.18
34.43
Price to Sales (TTM)
vs sector
6.08
8.57
Price to Book (MRQ)
vs sector
5.82
5.14
Price to Cash Flow (TTM)
vs sector
26.55
25.75
Total Debt to Equity (MRQ)
vs sector
11.45
15.12
LT Debt to Equity (MRQ)
vs sector
11.45
11.85
Return on Investment (TTM)
vs sector
17.94
13.54
Return on Equity (TTM)
vs sector
22.63
14.80

EXECUTIVE LEADERSHIP

P. Roy Vagelos
Chairman of the Board, Since 1995
Salary: --
Bonus: --
Leonard Schleifer
President, Chief Executive Officer, Director, Since 1994
Salary: $1,242,000.00
Bonus: --
Robert Landry
Chief Financial Officer, Senior Vice President - Finance, Since 2017
Salary: $585,600.00
Bonus: --
Daniel Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply, Since 2016
Salary: $349,200.00
Bonus: $282,852.00
Neil Stahl
Executive Vice President - Research and Development, Since 2014
Salary: $619,300.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

777 Old Saw Mill River Rd
TARRYTOWN   NY   10591-6717

Phone: +1914.3477000

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

SPONSORED STORIES